Compare BHVN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | LGND |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.9B |
| IPO Year | 2017 | 1992 |
| Metric | BHVN | LGND |
|---|---|---|
| Price | $11.54 | $189.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $29.79 | ★ $144.71 |
| AVG Volume (30 Days) | ★ 3.5M | 139.7K |
| Earning Date | 11-10-2025 | 08-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $181,488,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $2,219.74 | $18.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.40 |
| 52 Week Low | $7.48 | $81.74 |
| 52 Week High | $44.28 | $129.90 |
| Indicator | BHVN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 45.58 |
| Support Level | $8.29 | $179.65 |
| Resistance Level | $11.71 | $192.44 |
| Average True Range (ATR) | 0.72 | 6.57 |
| MACD | 0.47 | -2.06 |
| Stochastic Oscillator | 95.32 | 31.70 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.